D2-like multitarget ligands have alsodemonstrated theirpotential as therapeutically useful agents,25 especially in PD and schizophrenia treatment.26,27 In particular, combining D2R/D3R antagonism,5-HT1A receptor (5-HT1AR) agonism, and 5-HT2AR antagonism proved to be favorable in the management ofschizophrenia.5,28 Moreover, the simultaneous D2-like receptor and 5-HT1AR activation might beadvantageous in PD therapy. Here, DRD2 is linked to schizophrenia.